Remus Scripts a New Chapter—Launches Trial Material Subsidiary with Precision Dose

Ahmedabad, India, June 20, 2025 — Remus Pharmaceuticals Ltd. (REMP.NS) today announced the formation of a new clinical trial material management subsidiary as a strategic expansion into the high-growth clinical research support industry.

 

The new business will be specialized in the logistics, warehousing, and distribution of investigational medicinal products (IMPs) and associated supplies utilized in clinical trials. The move is another stride by Remus Pharma to increase its presence along the pharmaceutical value chain, particularly in high-integrity, regulatory-compliant trial support services. ".

 

Remus has been increasingly building out its international platform, with a heavy focus on neurology, cardiology, diabetes franchise, and critical care franchise, and has picked up pace in recent years on off-patent molecule development and new therapeutic areas. The new subsidiary will enable its clinical research partners in India and emerging markets to enhance operational effectiveness and regulatory compliance.

 

This expansion takes place as a rising demand for clinical trial infrastructure and support services, especially with India continuing to be a global hotspot for cost-effective and quality clinical research.

 

Sources: Remus Pharmaceuticals – Official Website, Economic Times, Remus Pharma